Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on September 13th, 2023%
A new award from National Institutes of Health funds preclinical work to prepare for a clinical trial assessing a treatment to reverse brain signaling damage in people with Alzheimer’s disease. . . . → Read More: Small Biz Grant Supports Regenerative Alzheimer’s Treatment
By Alan, on September 8th, 2023%
Researchers use stem cells to generate human neurons resembling those in the brain that control breathing during opioid reactions, for eventual chip devices to test overdose therapies. . . . → Read More: Neurons from Stem Cells Produced for Overdose Therapy Tests
By Alan, on September 4th, 2023% If you’ve used CBD for these reasons above, you might enjoy peace of mind knowing scientists have found the possible benefits you’ve known all along. . . . → Read More: What Science Has to Say About CBD
By Alan, on August 25th, 2023%
A clinical trial is underway testing a new type of therapy its developer says addresses damage to nerve cells associated with a number of neurological disorders. . . . → Read More: Trial Begins for Multi-Neurological Disease Therapy
By Alan, on August 21st, 2023%
A company developing a drug delivery process with treatments activated by ultrasound received an option to license a key technology from its founders’ university labs. . . . → Read More: Company Gains Ultrasound-Linked Drug Capsule Technology
By Alan, on August 4th, 2023%
A new company with a process using artificial intelligence and robotics to speed development of sustained release drugs is raising $4 million in seed funds. . . . → Read More: Long-Acting Drug Start-Up Raises $4M in Seed Funds
By Alan, on August 3rd, 2023%
A clinical trial assessing a synthetic antibody to generate an immediate response and also generate a more durable treatment for solid tumor cancers, advanced to a mid-stage study. . . . → Read More: Trial Advances of Dual-Action Cancer Immunotherapy
By Alan, on August 2nd, 2023%
A company, spun-off from academic labs that designs and produces new chemicals with artificial intelligence and robotics, is raising $42.7 million in its first venture funding round. . . . → Read More: Digital Chemistry Start-Up Gains $43M in Early Funds
By Alan, on July 25th, 2023%
A biotechnology company creating living tissue from a person’s stem cells says it received FDA clearance for a clinical trial of its replacement knee cartilage. . . . → Read More: Trial Cleared for Lab-Grown Replacement Knee Cartilage
By Alan, on July 20th, 2023%
A treatment for HIV taken just once, using the genome-editing technology Crispr, is receiving fast-track designation from the U.S. Food and Drug Administration. . . . → Read More: One-Time Crispr HIV Therapy Given Fast-Track Status
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|